ZALTRAP
As listed in the register: ZALTRAP 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION
25 mg/ml · concentrado para solución para perfusión
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Aflibercept
- Made by
- Sanofi Winthrop Industrie
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (EYLEA). It describes the substance, not this exact product.
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells.
VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-07
Safety of the active substance
From the US prescribing label for the same active substance (EYLEA). It describes the substance, not this exact product.
- Hypersensitivity reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation.
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
France1 matching products
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Sanofi Winthrop Industrie |
|---|---|
| Active substance | Aflibercept |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 25 mg/ml |
| Form | concentrado para solución para perfusión |
| Classification | L01XX44 · Cancer treatments and immune-system medicines |
| Route | vía intravenosa |
| Marketed | Yes, according to the register |
| Name in the register | ZALTRAP 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION |
| Nº Registro | 112814003 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- concentrado para solución para perfusión3 products
25 mg/ml3
25 mg/ml · 3 companies
- Sanofi Winthrop Industrie · this page
- Sanofi Winthrop Industrie
- Sanofi-Aventis Groupe
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.